Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Bms 907351
2. Bms-907351
3. Bms907351
4. Cabozantinib
5. Cometriq
6. Xl 184
7. Xl-184
8. Xl184 Cpd
1. 1140909-48-3
2. Cabozantinib Malate
3. Cabozantinib (s)-malate
4. Cabometyx
5. Cabozantinib Malate (xl184)
6. Xl184
7. Cabozantinib (s-malate)
8. Cometriq
9. Cabozantinib S-malate [usan]
10. Dr7st46x58
11. Bms907351
12. Chebi:72319
13. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate
14. Cabometyx (tn)
15. Cometriq (tn)
16. Cabozantinib Malate (jan)
17. 1-n-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2s)-2-hydroxybutanedioic Acid
18. Cabozantinib S-malate (usan)
19. Cabozantinib Malate [jan]
20. Unii-dr7st46x58
21. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
22. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
23. Xl184 Malate
24. Cabozantinib L-malate
25. Bms907351 Malate
26. Xl184(cabozantinib Malate)
27. Mls006010951
28. Chembl2103868
29. Dtxsid60915949
30. Ex-a2819
31. Mfcd20923480
32. S4001
33. 1140909-48-3 (malate)
34. Akos025401945
35. Cabozantinib S-malate [who-dd]
36. Ccg-270301
37. Cs-0201
38. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluor
39. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
40. Ac-27471
41. As-75255
42. Hy-12044
43. Smr004702755
44. Cabozantinib S-malate [orange Book]
45. Sw218093-2
46. D10095
47. Q27139901
48. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
49. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
50. (2s)-2-hydroxybutanedioic Acid; N'1-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
51. 1,1-cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4- Fluorophenyl)- Mono((2s)-2-hydroxybutanedioate)
52. Cyclopropane-1,1-dicarboxylic Acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, (s) Malate Salt
53. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Mono((2s)-2-hydroxybutanedioate)
54. N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate
55. N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2s)-2-hydroxybutanedioate
Molecular Weight | 635.6 g/mol |
---|---|
Molecular Formula | C32H30FN3O10 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 11 |
Exact Mass | 635.19152232 g/mol |
Monoisotopic Mass | 635.19152232 g/mol |
Topological Polar Surface Area | 194 Ų |
Heavy Atom Count | 46 |
Formal Charge | 0 |
Complexity | 924 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
* Renal Cell Carcinoma (RCC):
Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):
- in treatment-nave adults with intermediate or poor risk,
- in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.
Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.
* Hepatocellular Carcinoma (HCC):
Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
L01EX07
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Cabometyx (cabozantinib S-malate) is a oral TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Brand Name: Cabometyx
Study Phase: Approved FDFProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 26, 2025
Lead Product(s) : Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Exelixis Wins U.S. FDA Nod for CABOMETYX in Advanced Neuroendocrine Tumors
Details : Cabometyx (cabozantinib S-malate) is a oral TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.
Product Name : Cabometyx
Product Type : HPAPI
Upfront Cash : Inapplicable
March 26, 2025
Details:
AB521 (casdatifan) is a small-molecule inhibitor of HIF-2a, which is being evaluated for the treatment of clear cell renal cell carcinoma.
Lead Product(s): Casdatifan,Cabozantinib
Therapeutic Area: Oncology Brand Name: AB521
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 15, 2025
Lead Product(s) : Casdatifan,Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Data Shows Best-in-Class Potential for Casdatifan In Metastatic Kidney Cancer
Details : AB521 (casdatifan) is a small-molecule inhibitor of HIF-2a, which is being evaluated for the treatment of clear cell renal cell carcinoma.
Product Name : AB521
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2025
Details:
Cabometyx (cabozantinib S-malate) is a oral TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Brand Name: Cabometyx
Study Phase: Phase IIIProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 09, 2025
Lead Product(s) : Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Exelixis Provides Update on CABOMETYX® for Advanced Neuroendocrine Tumors
Details : Cabometyx (cabozantinib S-malate) is a oral TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.
Product Name : Cabometyx
Product Type : HPAPI
Upfront Cash : Inapplicable
January 09, 2025
Details:
Cabometyx (cabozantinib S-malate) is a TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Brand Name: Cabometyx
Study Phase: Phase IIIProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 26, 2024
Lead Product(s) : Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Exelixis Provides Regulatory Update for Supplemental New Drug Application for Cabozantinib
Details : Cabometyx (cabozantinib S-malate) is a TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.
Product Name : Cabometyx
Product Type : HPAPI
Upfront Cash : Inapplicable
November 26, 2024
Details:
Cabometyx (cabozantinib S-malate) is a TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Brand Name: Cabometyx
Study Phase: Phase IIIProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 16, 2024
Lead Product(s) : Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CABINET Ph III Final Results Reinforce Efficacy of Cabometyx in Neuroendocrine Tumors
Details : Cabometyx (cabozantinib S-malate) is a TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.
Product Name : Cabometyx
Product Type : HPAPI
Upfront Cash : Inapplicable
September 16, 2024
Details:
Cabometyx (Cabozantinib) tablet is a TK inhibitor, being investigated in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.
Lead Product(s): Cabozantinib,Atezolizumab
Therapeutic Area: Oncology Brand Name: Cabometyx
Study Phase: Phase IIIProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 15, 2024
Lead Product(s) : Cabozantinib,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ipsen Updates on CONTACT-02 Trial in Metastatic Castration-Resistant Prostate Cancer
Details : Cabometyx (Cabozantinib) tablet is a TK inhibitor, being investigated in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.
Product Name : Cabometyx
Product Type : HPAPI
Upfront Cash : Inapplicable
September 15, 2024
Details:
Cabometyx (cabozantinib S-malate) is a TK inhibitor which is being investigated for the treatment of patients with advanced pancreatic neuroendocrine tumors.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Brand Name: Cabometyx
Study Phase: Phase IIIProduct Type: HPAPI
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 08, 2024
Lead Product(s) : Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Exelixis Announces FDA Accepted the sNDA for Cabozantinib for Neuroendocrine Tumors
Details : Cabometyx (cabozantinib S-malate) is a TK inhibitor which is being investigated for the treatment of patients with advanced pancreatic neuroendocrine tumors.
Product Name : Cabometyx
Product Type : HPAPI
Upfront Cash : Inapplicable
June 08, 2024
Details:
Kura's lead product KO-2806, which is a Ftase inhibitor got dosing of the first patient in Phase I clinical trial studies in combination with cabozantinib for the treatment of Renal Cell Carcinoma.
Lead Product(s): KO-2806,Cabozantinib
Therapeutic Area: Oncology Brand Name: KO-2806
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 03, 2024
Lead Product(s) : KO-2806,Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tenax Therapeutics Announces Global License Amendment Expanding Rights to Levosimendan
Details : Kura's lead product KO-2806, which is a Ftase inhibitor got dosing of the first patient in Phase I clinical trial studies in combination with cabozantinib for the treatment of Renal Cell Carcinoma.
Product Name : KO-2806
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2024
Details:
The collaboration with Exelixis for the development of Cabometyx (cabozantinib S-malate) in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumor.
Lead Product(s): Cabozantinib
Therapeutic Area: Oncology Brand Name: Cabometyx
Study Phase: Phase IIIProduct Type: HPAPI
Sponsor: Exelixis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 07, 2024
Lead Product(s) : Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Exelixis
Deal Size : Undisclosed
Deal Type : Collaboration
Ipsen Expands Agreement for Cabometyx® in Neuroendocrine Tumors After CABINET Trial
Details : The collaboration with Exelixis for the development of Cabometyx (cabozantinib S-malate) in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumor.
Product Name : Cabometyx
Product Type : HPAPI
Upfront Cash : Undisclosed
February 07, 2024
Details:
Opdivo (nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor. It is being evaluated in combination with Cabometyx (cabozantinib) for first-line advanced renal cell carcinoma.
Lead Product(s): Nivolumab,Cabozantinib
Therapeutic Area: Oncology Brand Name: Opdivo
Study Phase: Approved FDFProduct Type: Antibody
Sponsor: Exelixis
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 22, 2024
Lead Product(s) : Nivolumab,Cabozantinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Exelixis
Deal Size : Inapplicable
Deal Type : Inapplicable
Opdivo® + CABOMETYX® Shows Long-Term Survival in CheckMate -9ER for Renal Cell Carcinoma
Details : Opdivo (nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor. It is being evaluated in combination with Cabometyx (cabozantinib) for first-line advanced renal cell carcinoma.
Product Name : Opdivo
Product Type : Antibody
Upfront Cash : Inapplicable
January 22, 2024
4-Chloro-6,7-dimethoxyquinoline
CAS Number : 35654-56-9
End Use API : Cabozantinib
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
1-((4-Fluoro phenyl) Carbamoyl) Cyclopropane Carbo...
CAS Number : 849217-48-7
End Use API : Cabozantinib
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
4-((6,7-Dimethoxyquinolin-4-yl)oxy)aniline
CAS Number : 190728-25-7
End Use API : Cabozantinib
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
Cyclopropane-1,1-dicarboxylic acid methyl ester
CAS Number : 113020-21-6
End Use API : Cabozantinib
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
1,1-Cyclopropanedicarboxylic acid
CAS Number : 598-10-7
End Use API : Cabozantinib
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
4-CHLORO-6,7-DIMETHOXYQUINOLINE
CAS Number : 35654-56-9
End Use API : Cabozantinib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...
CYCLOPROPANE-1,1-DICARBOXYLIC ACID
CAS Number : 598-10-7
End Use API : Cabozantinib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...
1-((4-FLUOROPHENYL)CARBAMOYL)CYCLOPROPANE-1- CARBO...
CAS Number : 849217-48-7
End Use API : Cabozantinib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...
4-((6,7-DIMETHOXY-QUINOLIN-4-YL)OXY)ANILINE
CAS Number : 190728-25-7
End Use API : Cabozantinib
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...
4-chloro-6,7-dimethoxyquinoline
CAS Number : 35654-56-9
End Use API : Cabozantinib
About The Company : We are into manufacturing of bulk drug Intermediates and Active Pharmaceutical Ingredients (API). Our core competence is contract manufacturing for our clients ...
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
82
PharmaCompass offers a list of Cabozantinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cabozantinib manufacturer or Cabozantinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cabozantinib manufacturer or Cabozantinib supplier.
PharmaCompass also assists you with knowing the Cabozantinib API Price utilized in the formulation of products. Cabozantinib API Price is not always fixed or binding as the Cabozantinib Price is obtained through a variety of data sources. The Cabozantinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cabozantinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cabozantinib, including repackagers and relabelers. The FDA regulates Cabozantinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cabozantinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cabozantinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cabozantinib supplier is an individual or a company that provides Cabozantinib active pharmaceutical ingredient (API) or Cabozantinib finished formulations upon request. The Cabozantinib suppliers may include Cabozantinib API manufacturers, exporters, distributors and traders.
click here to find a list of Cabozantinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cabozantinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Cabozantinib active pharmaceutical ingredient (API) in detail. Different forms of Cabozantinib DMFs exist exist since differing nations have different regulations, such as Cabozantinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cabozantinib DMF submitted to regulatory agencies in the US is known as a USDMF. Cabozantinib USDMF includes data on Cabozantinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cabozantinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cabozantinib suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cabozantinib Drug Master File in Korea (Cabozantinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cabozantinib. The MFDS reviews the Cabozantinib KDMF as part of the drug registration process and uses the information provided in the Cabozantinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cabozantinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cabozantinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cabozantinib suppliers with KDMF on PharmaCompass.
A Cabozantinib written confirmation (Cabozantinib WC) is an official document issued by a regulatory agency to a Cabozantinib manufacturer, verifying that the manufacturing facility of a Cabozantinib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cabozantinib APIs or Cabozantinib finished pharmaceutical products to another nation, regulatory agencies frequently require a Cabozantinib WC (written confirmation) as part of the regulatory process.
click here to find a list of Cabozantinib suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cabozantinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cabozantinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cabozantinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cabozantinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cabozantinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cabozantinib suppliers with NDC on PharmaCompass.
Cabozantinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cabozantinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cabozantinib GMP manufacturer or Cabozantinib GMP API supplier for your needs.
A Cabozantinib CoA (Certificate of Analysis) is a formal document that attests to Cabozantinib's compliance with Cabozantinib specifications and serves as a tool for batch-level quality control.
Cabozantinib CoA mostly includes findings from lab analyses of a specific batch. For each Cabozantinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cabozantinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Cabozantinib EP), Cabozantinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cabozantinib USP).